# US 2023/0176062 A1 · Devices and disposables for patient-specific cell therapy manufacturing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0176062 A1
- Document ID: US20230176062A1
- Status: Published application
- Kind: A1
- Application number: 18/083,279
- Filed: 2022-12-16
- Published: 2023-06-08
- Earliest claimed: 2007-12-07
- Assignees: Miltenyi Biotec GmbH
- Applicants: Miltenyi Biotec B.V. & Co. KG
- Inventors: Stefan Miltenyi; Winfried Schimmelpfennig; Holger Lantow; Niklas Elmar Neuschaefer; Martin Biehl; Eiad Kabaha; Juergen Schulz
- Web page: https://patentgrep.com/patent/US20230176062A1

## CPC

- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/19: Dendritic cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61M 1/0209: {Multiple bag systems for separating or storing blood components}
- A61M 1/3618: {Magnetic separation}
- A61M 1/3633: {Blood component filters, e.g. leukocyte filters}
- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- A61M 1/3692: {Washing or rinsing blood or blood constituents}
- A61M 1/3693: {using separation based on different densities of components, e.g. centrifuging}
- A61M 1/3696: {with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation}
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- B01D 15/3885: {using electrical or magnetic means}
- B01D 21/26: Separation of sediment aided by centrifugal force {or centripetal force}(centrifuges B04B; cyclones B04C)
- B03C 1/002: {High gradient magnetic separation (acting directly on the substance being separated B03C1/025; acting on the medium containing the substance being separated B03C1/32)}
- B03C 1/027: with reciprocating canisters
- B03C 1/032: Matrix cleaning systems
- B03C 1/0332: {using permanent magnets}
- B03C 1/0335: {using coils}
- B03C 1/034: characterised by the matrix elements
- B03C 1/288: {disposed at the outer circumference of a recipient}
- B04B 1/12: with continuous discharge
- B04B 5/00: Other centrifuges
- B04B 5/04: Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B 5/0442: {with means for adding or withdrawing liquid substances during the centrifugation, e.g. continuous centrifugation}
- B04B 5/10: Centrifuges combined with other apparatus, e.g. electrostatic separators; Sets or systems of several centrifuges (B04B5/12 takes precedence; magnetic or electrostatic separators B03C; {amassing particles by electric fields, e.g. by agglomeration B03C3/0175})
- B04B 7/08: Rotary bowls (centrifugal casting machines B22D)
- B04B 13/00: Control arrangements specially designed for centrifuges; Program control of centrifuges (control arrangements for feed, charge or discharge B04B11/00)
- C12M 23/28: {disposable or single use}
- C12M 33/10: {by centrifugation (centrifuges in general B04B); Cyclones (cyclones in general B04C)}
- C12M 41/48: {Automatic or computerized control (automatic analysis G01N35/00)}
- C12M 47/02: {Separating microorganisms from the culture medium; Concentration of biomass (separating microorganisms from their culture media C12N1/02)}
- C12M 47/04: {Cell isolation or sorting (purging biological preparations of unwanted cells C12N5/0081, determining the presence or kind of microorganism C12Q1/04)}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 5/0669: {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}
- G01N 35/0098: {involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation (magnetic particles used in immunoassays G01N33/54326; magnetic separation in general B03C)}
- A61M 1/3623: {Means for actively controlling temperature of blood}
- A61M 2202/0071: product to be retained or harvested, e.g. by pheresis
- A61M 2202/0413: Blood
- A61M 2202/0427: Platelets; Thrombocytes
- A61M 2202/10: Bone-marrow
- B01D 21/262: {by using a centrifuge}
- B01L 3/5021: {Test tubes specially adapted for centrifugation purposes}
- B03C 2201/18: Magnetic separation whereby the particles are suspended in a liquid
- B03C 2201/26: for use in medical or biological applications
- B04B 2005/0464: {with hollow or massive core in centrifuge bowl}
- B04B 2013/006: {Interface detection or monitoring of separated components}
- C12N 2500/34: Sugars
- C12N 2501/998: Proteins not provided for elsewhere
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- B03C: MAGNETIC OR ELECTROSTATIC SEPARATION OF SOLID MATERIALS FROM SOLID MATERIALS OR FLUIDS; SEPARATION BY HIGH-VOLTAGE ELECTRIC FIELDS (separating isotopes B01D59/00; combinations of magnetic or electrostatic separation with separation of solids by other means B03B, B07B)
- B04B: CENTRIFUGES (high-speed drum mills B02C19/11; domestic spin driers D06F; analysing, measuring or monitoring physical or chemical properties of samples during centrifuging, see the relevant subclasses for these procedures, e.g. G01N)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

The invention relates to a system, comprising: a) a sample processing unit, comprising an input port and an output port coupled to a rotating container having at least one sample chamber, the sample processing unit configured provide a first processing step to a sample or to rotate the container so as to apply a centrifugal force to a sample deposited in the chamber and separate at least a first component and a second component of the deposited sample; and b) a sample separation unit coupled to the output port of the sample processing unit, the cell separation unit comprising separation column holder (42), a pump (64) and a plurality of valves (1-11) configured to at least partially control fluid flow through a fluid circuitry and a separation column (40) positioned in the holder, the separation column configured to separate labeled and unlabeled components of sample flowed through the column.

## Claims

### Claim 1

A closed automatic system for manufacturing a therapeutic cell population for administration to a patient in need thereof,
wherein the system comprises a single-use assembly that includes the following components:
(1) a sample processing unit that includes an input port operably connected to a sample chamber, wherein the sample chamber comprises ports to supply fresh media and gasses to support culture of cells in the chamber and is configured to wash target cells and/or adjust volume of the sample as needed;
(2) a sample separation unit that includes a magnetic separation member, and
(3) fluid circuitry that interconnects the sample processing unit and the sample separation unit, so that cells can be caused to flow between the sample processing unit and the sample separation unit in either direction;
wherein the components of the assembly are constructed and arranged to receive a population of donor cells and to manufacture therefrom said therapeutic cell population by applying a process that comprises a plurality of steps selected from the following:
(a) positive or negative selection of a defined population of target cells using the magnetic separation member;
(b) activation or differentiation of cells by culturing with one or more cytokines or growth factors;
(c) transduction or transfection of cells by culturing with genetic material; and/or
(d) expansion of cells by culturing in fresh media;
and thereafter to wash and formulate the therapeutic cell population in an adjusted volume of injectable liquid;
wherein the system is closed and sterile, whereby said therapeutic cell population manufactured therewith is suitable for administration to a human patient;
wherein the single-use assembly is configured to be reversibly installed on a computer-controlled apparatus that operates the sample processing unit, the sample separation unit, and the fluid circuitry so as to manufacture the therapeutic cell population from the population of donor cells, after which the assembly maybe removed from the apparatus and replaced with another single-use assembly to process another population of donor cells.

### Claim 2 (depends on 1)

The system of claim 1, wherein the components of the single-use assembly are constructed and arranged for positive selection of target cells,
whereby target cells labeled with magnetic particles are retained in the magnetic separation member, while non-target cells that are not labeled with magnetic particles pass into a waste container.

### Claim 3 (depends on 1)

The system of claim 1, wherein the components of the single-use assembly are constructed and arranged for negative selection of target cells,
whereby non-target cells labeled with magnetic particles are retained in the magnetic separation member and discarded, while target cells that are not labeled with magnetic particles are retained.

### Claim 4 (depends on 1)

The system of claim 1, wherein the sample chamber comprises a plurality of layered surfaces that are configured so that cells can adhere to the surfaces when cultured in the chamber.

### Claim 5 (depends on 1)

The system of claim 1, wherein the sample chamber comprises a window or prism through which to monitor cells in the sample chamber during processing.

### Claim 6 (depends on 1)

The system of claim 1, wherein the sample processing unit is configured to remove unwanted cells by density separation.

### Claim 7 (depends on 1)

The system of claim 1, wherein the system further comprises said computer-controlled apparatus,
wherein the apparatus is configured to be reversibly installed with said single-use assembly, to operate the assembly to manufacture said therapeutic cell population from a population of donor cells, and to deliver the therapeutic cell population into a product collection container for administration to the patient.

### Claim 8 (depends on 7)

The system of claim 7, wherein the apparatus comprises a holder for the magnetic separation member, a pump operating on the fluid circuitry, and a plurality of valves that control flow through the fluid circuitry and the magnetic separation member of the single-use assembly.

### Claim 9 (depends on 7)

The system of claim 7, wherein the apparatus is controlled by a computer that is programmed to perform a plurality of said steps selected by an operator to manufacture said therapeutic cell population.

### Claim 10 (depends on 7)

The system of claim 7, wherein the computer is programmed to operate the apparatus to manufacture a genetically modified cell population from a donor cell population in the single-use assembly by performing the following steps:
(a) receive a sample of cells through the input port into the sample processing unit;
(b) prepare the sample of cells in the sample processing unit;
(c) transfer the prepared cells from the sample processing unit to the sample separation unit;
(d) separate the prepared cells into target cells and non-target cells in the sample separation unit using the magnetic separation member, allowing non-target cells to pass to a waste container,
(e) transfer the separated target cells back to the sample processing unit;
(f) combine and culture the target cells with genetic material in the sample chamber; supplying gas and fresh media as needed so as to genetically modify the cells;
(g) process the genetically modified cells by washing and adjusting volume; and thereafter
(h) deliver the genetically modified cells as a therapeutic cell population to a product collection container.

### Claim 11 (depends on 1)

A computer-controlled apparatus configured to be reversibly installed with a single-use assembly as put forth in claim 1, and thereafter to operate the assembly to manufacture a therapeutic cell population for a human subject in need thereof by applying to a population of donor cells a process that comprises a plurality of said processing steps.

### Claim 12 (depends on 1)

A method of using the system of claim 1 to manufacture a therapeutic cell population for administration to a patient in need thereof, the method comprising:
installing said single-use assembly on said computer controlled apparatus; and
directing the computer controlled apparatus to operate the single-use assembly to manufacture the therapeutic cell population from a population of donor cells.

### Claim 13 (depends on 12)

The method of claim 12, wherein the therapeutic cell population obtained thereby is genetically modified.

### Claim 14 (depends on 13)

The method of claim 13, wherein the system is directed to perform the following steps:
(a) receive a sample of cells through the input port into the sample processing unit;
(b) prepare the sample of cells in the sample processing unit;
(c) transfer the prepared cells from the sample processing unit to the sample separation unit;
(d) separate the prepared cells into target cells and non-target cells in the sample separation unit using the magnetic separation member, allowing non-target cells to pass to a waste container,
(e) transfer the separated target cells back to the sample processing unit;
(f) combine and culture the target cells with genetic material in the sample chamber; supplying gas and fresh media as needed so as to genetically modify the cells;
(g) process the genetically modified cells by washing and adjusting volume; and thereafter
(h) deliver the genetically modified cells as the therapeutic cell population to a product collection container.

### Claim 15 (depends on 12)

The method of claim 12, wherein the therapeutic cell population has been enriched for cells that are CD34 positive, CD133 positive, CD14 positive, and/or CD8 negative.

### Claim 16 (depends on 12)

The method of claim 12, wherein the therapeutic cell population is a population of stem cells or progenitor grafts from cord blood, a dendritic cell vaccine, an expanded population of T helper cells, or a population of antigen-specific T cells.
